Mefenorex
|
WikiDoc Resources for Mefenorex |
|
Articles |
|---|
|
Most recent articles on Mefenorex |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Mefenorex at Clinical Trials.gov Clinical Trials on Mefenorex at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Mefenorex
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Mefenorex Discussion groups on Mefenorex Directions to Hospitals Treating Mefenorex Risk calculators and risk factors for Mefenorex
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Mefenorex |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Mefenorex (Rondimen, Pondinil, Anexate) is a stimulant drug which was used as an appetite suppressant. It is an amphetamine derivative which was developed in the 1970s and used for the treatment of obesity.[1][2] Mefenorex produces amphetamine as a metabolite,[3] and has been withdrawn in many countries despite having only mild stimulant effects and relatively little abuse potential.[4]
References
- ↑ Vincendeau MJ. A new regulator of appetite: mefenorex. (French). Bordeaux Medical. 1970 Jul-Aug;3(7):1951-3.
- ↑ Beyer G, Huth K, Muller GM, Niemoller H, Raisp I, Vorberg G. The treatment of obesity with the appetite curbing agent Mefenorex. (German). Die Medizinische Welt. 1980 Feb;31(8):306-9.
- ↑ Rendic S, Slavica M, Medic-Saric M. Urinary excretion and metabolism of orally administered mefenorex. European Journal of Drug Metabolism and Pharmacokinetics. 1994 Apr-Jun;19(2):107-17.
- ↑ Engel J, Kristen G, Schaefer A, von Schlichtegroll A. Mefenorex (Rondimen). Drug and Alcohol Dependence. 1986 Jun;17(2-3):229-34.